A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
a study on Melanoma Skin Cancer/Melanoma Breast Cancer Hepatocellular Carcinoma Liver Cancer Transitional Cell Carcinoma Head and Neck Cancer Head and Neck Squamous Cell Carcinoma Squamous Cell Carcinoma Kidney Cancer Renal Cell Carcinoma Colorectal Cancer Lung Cancer Non-Small Cell Lung Cancer Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Cancer Endometrial Cancer Mesothelioma Neuroendocrine Carcinoma Cervical Cancer Prostate Cancer Nasopharyngeal Cancer Cholangiocarcinoma Basal Cell Carcinoma Ovarian Cancer Fallopian Tube Cancer Thymoma Thymic Carcinoma Vulvar Carcinoma Solid Tumor Malignant Adnexal Neoplasms Non-squamous Cell Salivary Gland Carcinoma
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at San Diego, California and other locations
- Dates
- study startedestimated completion
Description
Summary
This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb20717, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb20717 in subjects with selected advanced solid tumors.
Official Title
A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
Keywords
Melanoma Breast Carcinoma Hepatocellular Carcinoma Urothelial Carcinoma Squamous Cell Carcinoma of the Head and Neck Renal Cell Carcinoma Colorectal Carcinoma Non-small Cell Lung Carcinoma Gastric or Gastroesophageal Junction Adenocarcinoma Endometrial Carcinoma Mesothelioma Neuroendocrine Carcinoma Cervical Cancer Small Cell Lung Carcinoma Squamous Cell Carcinoma of the Anus Castration-Resistant Prostate Carcinoma Nasopharyngeal Carcinoma Cholangiocarcinoma Basal Cell Carcinoma Ovarian Carcinoma Fallopian Tube Carcinoma Thymoma Thymic Carcinoma Squamous Cell Carcinoma of the Penis Vulvar Carcinoma Solid Tumors With Published Evidence of Anti-tumor Activity With Anti-PD1/PDL1 and/or Anti-CTLA4-directed Therapy Malignant Adnexal Neoplasms Non-squamous Cell Salivary Gland Carcinoma DUET-2 Triple Negative Breast Cancer Hepatocellular Cancer Urothelial Cancer Renal Cell Cancer Head and Neck Cancer MSI-high Colorectal Cancer MSI-high Endometrial Cancer Non-small Cell Lung Cancer Gastric Cancer Gastroesophageal Junction Cancer High-grade Neuroendocrine Cancer Small Cell Lung Cancer Anal Cancer Prostate Cancer Nasopharyngeal Cancer Bile Duct Cancer Basal Cell Skin Cancer Ovarian Cancer Fallopian Tube Cancer Malignant Adnexal Tumor Thymus Cancer Penile Cancer Vulvar Cancer Salivary Gland Cancer Carcinoma Carcinoma, Squamous Cell Uterine Cervical Neoplasms Mesothelioma, Malignant Breast Neoplasms Lung Neoplasms Carcinoma, Basal Cell Squamous Cell Carcinoma of Head and Neck Colorectal Neoplasms Endometrial Neoplasms Carcinoma, Non-Small-Cell Lung Carcinoma, Neuroendocrine Anus Neoplasms Vulvar Neoplasms XmAb20717
Eligibility
You can join if…
Open to people ages 18 years and up
- Histologically or cytologically confirmed diagnosis of one of the following advanced solid tumors:
PART A (Dose Escalation Cohorts)
- Melanoma;
- Breast carcinoma that is estrogen receptor, progesterone receptor, and Her2 negative (triple-negative breast cancer; TNBC);
- Hepatocellular carcinoma;
- Urothelial carcinoma;
- Squamous cell carcinoma of the head and neck;
- Renal cell carcinoma (clear cell predominant type);
- Microsatellite instability-high or mismatch repair deficient colorectal carcinoma or endometrial carcinoma;
- Non-small cell lung carcinoma;
- Gastric or gastroesophageal junction adenocarcinoma
- . Mesothelioma;
- . High-grade neuroendocrine carcinoma, including small cell carcinoma of the lung
- . Cervical cancer;
- . Squamous cell carcinoma of the anus
PART B (Dose Expansion Cohorts):
- Melanoma
- Renal cell carcinoma (clear cell predominant type)
- Non-small cell lung carcinoma
- Castrate-resistant adenocarcinoma of the prostate, defined as progressive disease after surgical castration, or progression in the setting of medical androgen ablation with a castrate level of testosterone (< 50 ng/dL)
- Nasopharyngeal carcinoma
- Cholangiocarcinoma
- Basal cell carcinoma
- Squamous cell carcinoma of the anus
- Mesothelioma
- . Ovarian or fallopian tube carcinoma
- . Malignant adnexal neoplasms (including, but not limited to, sebaceous carcinoma, trichilemmal carcinoma, pilomatrix carcinoma, eccrine carcinoma, hidradenocarcinoma, adnexal carcinoma with divergent differentiation, papillary digital eccrine adenocarcinoma, microcystic adnexal carcinoma, and clear cell eccrine carcinoma)
- . Thymoma
- . Thymic carcinoma
- . Squamous cell carcinoma of the penis
- . Neuroendocrine carcinoma
- . Vulvar cancer
- . Non-squamous cell salivary gland carcinoma (except adenoid cystic carcinoma)
- . Subjects with other solid tumors for which there is published evidence of anti-tumor activity with anti-PD1/PDL1 and/or anti-CTLA4-directed therapy but for which there is no FDA-approved anti-PD1/PDL1 or CTLA4-directed checkpoint inhibitor treatment may be eligible for Part B after approval by the Medical Monitor.
- All subjects' cancer must have progressed after treatment with all standard therapies or have no appropriate available therapies.
- Subjects, except those with adenocarcinoma of the prostate, must have measurable disease by RECIST 1.1.
- Have available adequate archival formalin-fixed paraffin-embedded block(s)/slides containing tumor or adequate pre-dose fresh tumor biopsy tissue
- ECOG performance status of 0 - 1
- Subjects with adenocarcinoma of the prostate must have evaluable disease (measurable or nonmeasurable lesions) by PCWG3.
You CAN'T join if...
- Subjects currently receiving other anticancer therapies, with the exception of subjects with adenocarcinoma of the prostate, who may continue luteinizing hormone-releasing hormone (LHRH) analogue therapy.
- Treatment with any CTLA4 antibody within 6 weeks of the start of study drug.
- Treatment with nivolumab or any PDL1 or PDL2-directed antibody within 4 weeks of the start of study drug.
- Treatment with pembrolizumab within 4 - 12 weeks of the start of study drug (cohort dependent).
- Treatment with any other anticancer therapy within 2 weeks of the start of study drug (i.e., other immunotherapy, chemotherapy, radiation therapy, etc.). Subjects with prostate cancer may continue LHRH analogue therapy.
- A life-threatening (Grade 4) immune-mediated AE related to prior immunotherapy.
- Failure to recover from any immune-related toxicity from prior cancer therapy to ≤ Grade 1, except if previous immune-related endocrinopathy is medically managed with hormone replacement therapy only.
- Failure to recover from any other toxicity (other than immune-related toxicity) related to previous anticancer treatment to ≤ Grade 2.
- Have known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, ie, are without evidence of progression for at least 4 weeks by repeat imaging, are clinically stable, and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment.
- Active known or suspected autoimmune disease (except that subjects are permitted to enroll if they have vitiligo; type 1 diabetes mellitus or residual hypothyroidism due to an autoimmune condition that is treatable with hormone replacement therapy only; psoriasis, atopic dermatitis, or another autoimmune skin condition that is managed without systemic therapy; or arthritis that is managed without systemic therapy beyond oral acetaminophen and non-steroidal anti-inflammatory drugs).
- Has any condition requiring systemic treatment with corticosteroids, prednisone equivalents, or other immunosuppressive medications within 14 days prior to first dose of study drug (except that inhaled or topical corticosteroids or brief courses of corticosteroids given for prophylaxis of contrast dye allergic response are permitted).
- Receipt of an organ allograft.
- Prior treatment with any checkpoint inhibitor therapy regimen that targets both PD1/L1 and CTLA-4.
Locations
- University of California San Diego Moores Cancer Center
accepting new patients
San Diego California 92093-0698 United States - UCLA Hematology-Oncology Clinic (Westwood)
accepting new patients
Los Angeles California 90095 United States
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Xencor, Inc.
- ID
- NCT03517488
- Phase
- Phase 1 Research Study
- Study Type
- Interventional
- Participants
- Expecting 154 study participants
- Last Updated
Please contact me about this study
We will not share your information with anyone other than the team in charge of this study. Submitting your contact information does not obligate you to participate in research.
Thank you!
The study team should get back to you in a few business days.